• Maria Leon Roux (Chair), Environment and Radiation Section, IARC
• Neela Guha, IARC Monographs, IARC
• Eva Kralikova, Charles University, Czech Republic
• Anne McNeill², UK Centre for Tobacco Control Studies, United Kingdom
• Silvia Minozzi, CPO Piemonte, AO Città della Salute e della Scienza di Torino, Italy
• Armando Peruga, Tobacco Free Initiative, World Health Organization (WHO)
• Joachim Schüz (PI representative), Environment and Radiation Section, IARC
• Carolina Espina (Rapporteur), Environment and Radiation Section, IARC

² The university department to which A. McNeill belongs receives research grants from governmental and non-governmental (but not commercial) organizations for carrying out research in the tobacco control field.

• Isabelle Romieu (co-Chair), Nutrition and Metabolism Section, IARC
• Martin Wiseman (co-Chair), World Cancer Research Fund, United Kingdom
• Annie Anderson, Ninewells Hospital and Medical School, United Kingdom
• Paola Armaroli, CPO Piemonte, AO Città della Salute e della Scienza di Torino, Italy
• Franco Berrino, Fondazione IRCSS Istituto Nazionale dei Tumori, Italy
• Marie-Christine Boutron-Ruault, Institut Gustave Roussy, France
• Michele Cecchini, Health Policy Analyst OECD, France Tim Key, University of Oxford, United Kingdom
• Timothy J. Key, University of Oxford, United Kingdom
• Michael Leitzmann, University of Regensburg, Germany
• Teresa Norat, Imperial College London, United Kingdom
• Hilary J Powers, University of Sheffield, United Kingdom
• Chiara Scoccianti, Nutrition and Metabolism Section, IARC
• Joachim Schüz (PI representative), Environment and Radiation Section, IARC
• Lawrence von Karsa (PI representative), Quality Assurance Group, Early Detection and Prevention Section, IARC
• Carolina Espina (Rapporteur), Environment and Radiation Section, IARC

• Joachim Schüz (Chair), Environment and Radiation Section, IARC
• Anssi Auvinen, University of Tampere School of Health Sciences and Radiation and Nuclear Safety Authority, Finland
• Esther de Vries, Department of Public Health Erasmus MC, The Netherlands
•  Friederike Erdmann, Environment and Radiation Section, IARC
• Rüdiger Greinert, Elbekliniken Stade/Buxtehude, Germany
• John Harrison, Public Health England, United Kingdom
• Ausrele Kesminiene, Environment and Radiation Section, IARC
• Neil McColl, Public Health England, United Kingdom
• Carolina Espina (Rapporteur), Environment and Radiation Section, IARC

• Joachim Schüz (Chair), Environment and Radiation Section, IARC
• Søren Friis³, Danish Cancer Society Research Center, Danish Cancer Society, Denmark
• Manolis Kogevinas, Centre for Research in Environmental Epidemiology (CREAL), Spain
• Rodolfo Saracci, Education and Training Group, IARC
• Kurt Straif, IARC Monographs Section, IARC
• Harri Vainio, Finnish Institute of Occupational Health, Finland
• Carolina Espina (Rapporteur), Environment and Radiation Section, IARC

³ The Danish Cancer Society Research Center where S. Friis is employed received 138,000 Euros from Lundbeck A/S to perform an observational epidemiological study of the association between memantine and risk of prostate cancer. The study was requested by the European Medicines Agency (EMA). The funding ceased in 2013.

• Rolando Herrero (Chair), Prevention and Implementation Group, Early Detection and Prevention Section, IARC
• Maribel Almonte, Prevention and Implementation Group, Early Detection and Prevention Section, IARC
• Ahti Anttila, Mass Screening Registry/Finnish Cancer Registry, Finland
• Hugo De Vuyst, Prevention and Implementation Group, Early Detection and Prevention Section, IARC
• Joakim Dillner⁴, Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Sweden
• Silvia Franceschi, Infections and Cancer Epidemiology Group, Infections Section, IARC
• Paula Gonzalez, Prevention and Implementation Group, Early Detection and Prevention Section, IARC
• Andrew Hall, London School of Hygiene and Tropical Medicine, United Kingdom
• Jin Young Park, Prevention and Implementation Group, Early Detection and Prevention Section, IARC
• Lawrence von Karsa (PI representative), Quality Assurance Group, Early Detection and Prevention Section, IARC
• Patricia Villain (Rapporteur), Quality Assurance Group, Early Detection and Prevention Section, IARC

⁴ J. Dillner has received research grants to his university with significant funding from Merck/SPMSD, a manufacturer of HPV vaccines, for monitoring studies on HPV vaccines. He declares no personal remuneration.

• Nereo Segnan (Chair), Quality Assurance Group, Early Detection and Prevention Section, IARC
• Maribel Almonte, Prevention and Implementation Group, Early Detection and Prevention Section, IARC
• Ahti Anttila, Mass Screening Registry/Finnish Cancer Registry, Finland
• Paola Armaroli, CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin, Italy
• Wendy Atkin⁵, Imperial College London, United Kingdom
• Peter B. Dean, Quality Assurance Group, Early Detection and Prevention Section, IARC and University of Turku, Faculty of Medicine, Finland
• Harry de Koning⁶, Erasmus MC University Medical Center, The Netherlands
• Lena Dillner, Karolinska University Hospital, Sweden
• Rolando Herrero, Prevention and Implementation Group, Early Detection and Prevention Section, IARC
• Ernst Kuipers, Erasmus MC University Medical Center, The Netherlands
• Iris Lansdorp-Vogelaar, Erasmus MC University Medical Center, The Netherlands
• Eugenio Paci, Clinical and Descriptive Epidemiology Unit ISPO, Italy
• Jaroslaw Regula, Maria Sklodowska-Curie Memorial Cancer Center Department of Gastroenterology, Poland
• Eero Suonio, Quality Assurance Group, Early Detection and Prevention Section, IARC
• Sven Törnberg, Stockholm Regional Cancer Centre, Sweden
• Lawrence von Karsa (PI representative), Quality Assurance Group, Early Detection and Prevention Section, IARC
• Patricia Villain (Rapporteur), Quality Assurance Group, Early Detection and Prevention Section, IARC

⁵ W. Atkin has received significant non-monetary research support from Eiken Chemicals for reagents and machine lease for processing immunochemical faecal occult blood tests. The support is on-going and the monetary equivalent of the in-kind support received will total less than £80,000.

⁶ The Department of Public Health of the Erasmus University Medical Center where H. de Koning is employed received an 80,000 Euro grant from Beckman in 2011 for research on the cost-effectiveness of phi-testing for prostate cancer. The support ended in 2014.